Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Twist Bioscience Corporation (NASDAQ: TWST) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a mid-cap growth and value biotech company focused on synthetic DNA tools and a silicon-based DNA synthesis platform, Twist uses its filings to report financial performance, governance changes and other material events.
Investors can review current and historical 8-K reports, which for Twist have included announcements of quarterly and full-year financial results, as well as board and committee changes. For example, recent 8-K filings describe the release of financial results for specific quarters and fiscal years, and the appointment of a new director to the board and audit committee, along with associated compensation arrangements.
In addition to 8-Ks, users can access Twist’s annual reports on Form 10-K and quarterly reports on Form 10-Q via the SEC feed. These documents typically contain detailed discussions of results of operations, risk factors, and business descriptions related to Twist’s synthetic DNA platform, research tools and geographic operations. Proxy materials and equity compensation plan disclosures can also be reviewed to understand governance practices and incentive structures.
Stock Titan enhances these filings with AI-powered summaries that highlight key points, helping readers quickly interpret complex documents such as lengthy 10-Ks or detailed 10-Qs. Real-time updates from EDGAR ensure that new filings appear promptly, while Form 4 and related insider transaction reports can be monitored to see equity awards and other reportable insider activity. Together, these resources support a deeper understanding of TWST’s regulatory disclosures and corporate developments.
Twist Bioscience (TWST) Form 144 notice: An insider proposes to sell 918 shares of common stock through Fidelity Brokerage Services on 08/21/2025, with an aggregate market value of $23,835.14. The shares were acquired by restricted stock vesting on 08/20/2025 and are being sold as compensation. The issuer has 60,360,925 shares outstanding, making this proposed sale a very small portion of the outstanding shares. The filing also discloses prior insider sales by Adam Laponis of 936 shares on 05/21/2025 (gross proceeds $27,843.57) and 2,449 shares on 07/09/2025 (gross proceeds $93,419.31). The notice includes the standard insider certification that no undisclosed material adverse information is known to the seller.
Form 144 notice from Twist Bioscience (TWST) shows an insider sale filing for common stock. The filer plans to sell 238 shares via Fidelity Brokerage Services on NASDAQ with an aggregate market value of $6,179.48 and an approximate sale date of 08/21/2025. The shares were acquired on 08/20/2025 through restricted stock vesting and were received as compensation. The filing lists four prior small common-stock sales by Robert Werner totaling 1,492 shares between 05/21/2025 and 08/04/2025 with gross proceeds reported for each sale. The notice includes the standard certification that the signer is unaware of undisclosed material adverse information.
Twist Bioscience (TWST) insider sale notice: This Form 144 reports a proposed sale of 521 common shares by an insider through Fidelity Brokerage Services with an aggregate market value of $13,527.35. The company has 60,360,925 shares outstanding and the sale is planned for 08/21/2025 on NASDAQ.
The shares were acquired on 08/20/2025 by restricted stock vesting as compensation and became payable on the same date. The filer previously sold common shares in six transactions between 05/21/2025 and 08/04/2025, totaling 2,022 shares for gross proceeds of $60,115.91. The filer certifies no undisclosed material adverse information.
Artisan Partners and several affiliated entities report beneficial ownership of 5,061,033 shares of Twist Bioscience common stock, equal to 8.4% of the outstanding class based on 59,916,141 shares outstanding as of 05/01/2025. The filing shows shared voting power of 4,078,039 shares and no sole voting or dispositive power reported.
The shares were acquired for and are held on behalf of discretionary clients of Artisan Partners Limited Partnership. The filing includes a certification that the holdings are held in the ordinary course of business and were not acquired to change or influence control of the issuer. No other person is reported to have an economic interest above 5% in these shares.
FAQ
What is the current stock price of Twist Bioscience (TWST)?
What is the market cap of Twist Bioscience (TWST)?
